Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) reported positive results from two Phase 3 studies of the tezacaftor (VX-661)/ivacaftor combination treatment for cystic fibrosis sending the stock price soaring $18.34 to close at $108.01.
Vertex Pharmaceuticals reports positive data
March 29, 2017 at 18:13 PM EDT
